T-Cell Response

Advertisement

cGxPJobs Banner

MAIA Advances Phase 3 Ateganosine Trial in Advanced NSCLC

CHICAGO — September 22, 2026 MAIA Biotechnology announced that enrollment has reached 65 patients in the pivotal Phase 3...

By cGxPwire Editor
September 24, 2026

Read More

Advertisement

cGxPJobs

Directory